Drug intelligence / Profile preview

amoxicillin + clavulanic acid + cefuroxime

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

This combination is not a standard or commonly used formulation. However, each component is an antibiotic. **Amoxicillin** and **clavulanic acid** are used together to treat infections caused by bacteria that produce beta-lactamase enzymes, which can inactivate amoxicillin. **Cefuroxime** is a cephalosporin antibiotic effective against a wide range of bacterial infections. The combination of these drugs would theoretically provide broad-spectrum coverage against various bacterial infections, including those resistant to amoxicillin alone.

Targets

PBP (Penicillin-binding protein family)β-lactamase

Beyond the preview

Go deeper on amoxicillin + clavulanic acid + cefuroxime.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on amoxicillin + clavulanic acid + cefuroxime.

Explore the full profile